The number of new trials rose in 2018, but sponsor investment in research and development remained steady, a new survey shows.
Phase 1 through phase 3 trial starts rose 12 percent in 2018 to 7,606, up from 6,794 in 2017, according to an Informa survey. Phase 1 starts totaled 2,900, up 3 percent, while phase 2 fell 4 percent to 2,469. Phase 3 trials held their ground with 1,373, less than a 1 percent increase.